ACT Genomics joins the TMB Harmonization Project to standardize the calculation of tumor mutational burden (TMB). TMB is the number of mutations harbored by the tumor and an important biomarker that helps predict the likelihood a cancer patient will benefit from immunotherapy. To ensure consistency when evaluating immunotherapy for patients, the harmonization project convened major stakeholders to create standardization for TMB calculation and reporting across different testing panels.
The project will conduct analytical validation to identify the source of variability among different tests and to create a reference standard, followed by clinical validation using retrospective analysis.
More info on the project: https://www.focr.org/tmb